(Q44291819)

17 December 2019

title

A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

main subject

phase II clinical trial

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Andrea B. Troxel

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Karen H. Antman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

author name string

Amy D Tiersten

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Caron Nelsen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Susan Talbot

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Robert Fine

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Lois Brafman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Laureen Shriberg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Daniel P Petrylak

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

language of work or name

English

0 references

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

page(s)

537-544

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548594%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Estramustine phosphate inhibits microtubule assembly by binding to the microtubule-associated proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Modulation of the function of P-glycoprotein by estramustine.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Estracyt in advanced carcinoma of the breast: A phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.11082

1 reference

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021

Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11082

7 January 2021